Diabetic nephropathy in African-American patients

被引：74

作者：

Crook E.D. ^{[1
]}

Patel S.R. ^{[1
]}

机构：

[1] University Health Clinic, Wayne State Univ. School of Medicine, Detroit, MI 48201

来源：

Current Diabetes Reports | 2004年 / 4卷 / 6期

关键词：

Glycemic Control; Diabetic Nephropathy; Irbesartan; Microvascular Complication; Renal Survival;

D O I：

10.1007/s11892-004-0056-y

中图分类号：

学科分类号：

摘要：

Diabetic nephropathy (DN) is the number one cause of end-stage renal disease (ESRD) in the United States and is highly prevalent in African Americans. Since 1997, DN has been the number one cause of ESRD in African Americans. In African Americans, almost all DN is due to type 2 diabetes mellitus (T2DM), and nephropathy may affect female more than male patients. African Americans with T2DM are at increased risk for developing and having progression of DN. Glycemic control, development of albuminuria, family history of renal disease, and control of blood pressure are important risk factors for progression of DN. In addition, cigarette smoking, presence of hepatitis C, and use of thiazolinediones has an impact on renal survival in African Americans. Large vessel complications may be less frequent in African Americans with T2DM, when compared with white persons. Yet, cardiovascular disease and other microvascular complications are very common, and both are dependent on control of blood pressure. Achieving the recommended blood pressure of less than 130/80 mm Hg is essential but requires multiple antihypertensive medications, including an inhibitor of the renin-angiotensin system. Copyright © 2004 by Current Science Inc.

引用

页码：455 / 461

页数：6

共 53 条

[1]

Hsu C., Vittinghoff E., Lin F., Shilpak M.G., The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency, Ann. Intern. Med., 141, pp. 95-101, (2004)

[2]

Crook E.D., Diabetic renal disease in African Americans, Am. J. Med. Sci., 323, pp. 78-84, (2002)

[3]

Brancati F.L., Whelton P.K., Randall B.L., Et al., Risk of end-stage renal disease in diabetes mellitus: A prospective cohort study of men screened for MRFIT. Multiple Risk Factor Intervention Trial, JAMA, 278, pp. 2069-2074, (1997)

[4]

Brancati F.L., Whittle J.C., Whelton P.K., Et al., The excess incidence of diabetic end-stage renal disease among blacks: A population-based study of potential explanatory factors, JAMA, 268, pp. 3079-3084, (1992)

[5]

Carter J.S., Pugh J.A., Monterrosa A., Non-insulin-dependent diabetes mellitus in minorities in the United States, Ann. Intern. Med., 125, pp. 221-232, (1996)

[6]

Powers D.R., Wallin J.D., End-stage renal disease in specific ethnic and racial groups: Risk factors and benefits of antihypertensive therapy, Arch. Intern. Med., 158, pp. 793-800, (1998)

[7]

Kramer H.J., Nguyen Q.D., Curhan G., Hsu C.Y., Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus, JAMA, 289, pp. 3273-3277, (2003)

[8]

Young B.A., Maynard C., Boyko E.J., Racial differences in diabetic nephropathy, cardiovascular disease and mortality in national population of veterans, Diabetes Care, 26, pp. 2392-2399, (2003)

[9]

Krop J.S., Coresh J., Chambless L.E., Et al., A community-based study of explanatory factors for the excess risk for early renal function decline in blacks vs. whites with diabetes: The Atherosclerosis Risk in Communities study, Arch. Intern. Med., 159, pp. 1777-1783, (1999)

[10]

Crook E.D., Harris J., Oliver B., Et al., Endstage renal disease due to diabetic nephropathy in Mississippi: An examination of factors influencing renal survival in a population prone to late referral, J. Invest. Med., 49, pp. 284-291, (2001)

← 1 2 3 4 5 6 →